Galmed Pharmaceuticals Ltd. (GLMD) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) from a hold rating to a buy rating in a research report released on Wednesday morning. They currently have $5.00 target price on the biopharmaceutical company’s stock.
According to Zacks, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel. “
A number of other research analysts have also recently weighed in on GLMD. HC Wainwright reaffirmed a buy rating on shares of Galmed Pharmaceuticals in a report on Thursday, June 30th. Roth Capital reaffirmed a buy rating and issued a $6.00 price objective on shares of Galmed Pharmaceuticals in a report on Wednesday, July 6th. Maxim Group reaffirmed a buy rating on shares of Galmed Pharmaceuticals in a report on Wednesday, June 8th. Finally, FBR & Co set a $20.00 price objective on shares of Galmed Pharmaceuticals and gave the company a buy rating in a report on Friday, August 5th. Five equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and a consensus target price of $12.40.
Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) traded down 0.2186% during midday trading on Wednesday, hitting $4.6099. 2,013 shares of the stock were exchanged. The firm’s 50-day moving average is $4.18 and its 200-day moving average is $4.71. The stock’s market cap is $51.18 million. Galmed Pharmaceuticals has a 12 month low of $3.50 and a 12 month high of $10.20.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.04. Equities research analysts predict that Galmed Pharmaceuticals will post ($1.51) earnings per share for the current year.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Stock Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.